Zeo Scientifix, Inc income statement ZEOX

Annual Quarterly

In Q2 of fiscal 2026, the quarter ended Apr 30, 2026, Zeo Scientifix, Inc reported revenue of $2.6 million, up 124.6% from the same quarter a year earlier. It recorded a net loss of $145,000. The operating loss came to $512,000, an operating margin of -19.8%. Diluted earnings per share were -$0.02.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Apr 30, 2026	Q2 FY2026 Apr 30, 2026	Q1 FY2026 Jan 31, 2026	Q3 FY2025 Jul 31, 2025	Q2 FY2025 Apr 30, 2025	Q1 FY2025 Jan 31, 2025	Q4 FY2024 Oct 31, 2024	Q3 FY2024 Jul 31, 2024	Q2 FY2024 Apr 30, 2024
Revenue	—	3 +124.6%	1 +32.7%	1 +19.7%	1 +1.6%	1 -5.5%	1 -12.5%	1 -10.6%	1 +33.8%
Cost of revenue	—	1 +105.5%	0 +47.1%	0 +29.5%	0 -9.9%	0 +20.1%	0 +69.2%	0 +8.6%	0 +163.0%
Gross profit	—	2 +130.1%	1 +29.6%	1 +17.8%	1 +5.4%	1 -9.6%	1 -20.9%	1 -13.6%	1 +14.9%
Research and development	—	0	0	—	—	—	—	0 -77.6%	0 -98.8%
Selling, general and administrative	—	3 +22.6%	2 -2.0%	3 +51.2%	2 -5.1%	2 -0.2%	2 -3.1%	2 -16.8%	2 -9.0%
Operating income	—	-1 +63.3%	-1 +29.9%	-2 -77.3%	-1 +10.9%	-1 -7.8%	-1 -15.7%	-1 +19.2%	-2 +18.2%
Net income	—	-0 +89.6%	-1 +31.5%	-2 -104.7%	-1 +0.6%	-1 -19.5%	-1 -14.9%	-1 +37.5%	-1 +29.7%
Basic EPS	—	-0.02 +90.9%	-0.12 +40.0%	-0.32 -100.0%	-0.22 +4.3%	-0.20 -17.6%	-0.19 -22.9%	-0.16 +30.4%	-0.23
Diluted EPS	—	-0.02 +90.9%	-0.12 +40.0%	-0.32 -100.0%	-0.22 +4.3%	-0.20 -17.6%	-0.19 -22.9%	-0.16 +30.4%	-0.23
Weighted average shares, basic	—	8 +22.3%	7 +10.7%	6 +2.3%	6 +2.8%	6 +2.5%	7 -6.5%	6 -11.9%	6
Weighted average shares, diluted	—	8 +22.3%	7 +10.7%	6 +2.3%	6 +2.8%	6 +2.5%	7 -6.5%	6 -11.9%	6
Other measures
Depreciation and amortization	—	0 +18.8%	0 +5.6%	0 +5.6%	0 -15.8%	0 -5.3%	0 +12.5%	0 -88.6%	0 -87.8%
EBITDA	—	-0 +64.2%	-1 +30.4%	-2 -78.4%	-1 +10.8%	-1 -8.0%	-1 -15.7%	-1 +10.7%	-2 +12.1%
Interest coverage	—	-46.55x	-87.80x	-90.04x	-66.38x	-56.95x	-64.77x	-50.78x	-78.20x
Margins
Gross margin	—	79.62%	80.57%	82.54%	77.72%	82.48%	81.91%	83.87%	74.89%
Operating margin	—	-19.84%	-60.72%	-158.58%	-121.32%	-114.95%	-114.55%	-107.06%	-138.28%
Profit margin	—	-5.62%	-58.92%	-158.65%	-121.06%	-114.04%	-100.80%	-92.76%	-123.70%
EBITDA margin	—	-19.10%	-59.41%	-157.12%	-119.93%	-113.30%	-113.10%	-105.41%	-136.60%

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: ZEOX (OTC)
Fiscal year ends: June 30
Incorporated in: NV
Headquarters: Davie, FL
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1557376
Former names: Organicell Regenerative Medicine, Inc. (until Jan 29, 2024); Biotech Products Services & Research, Inc. (until Jun 15, 2018); BESPOKE TRICYCLES INC (until Sep 14, 2015)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.